LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 677

Search options

  1. Article ; Online: Lack of Benefit of Renin-Angiotensin System Inhibitors in COVID-19.

    Lee, Matthew M Y / McMurray, John J V

    JAMA

    2023  Volume 329, Issue 14, Page(s) 1155–1156

    MeSH term(s) Humans ; Angiotensin-Converting Enzyme Inhibitors/pharmacology ; Angiotensin-Converting Enzyme Inhibitors/therapeutic use ; Antihypertensive Agents/pharmacology ; COVID-19/therapy ; COVID-19 Drug Treatment/methods ; Renin-Angiotensin System/drug effects
    Chemical Substances Angiotensin-Converting Enzyme Inhibitors ; Antihypertensive Agents
    Language English
    Publishing date 2023-04-11
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 2958-0
    ISSN 1538-3598 ; 0254-9077 ; 0002-9955 ; 0098-7484
    ISSN (online) 1538-3598
    ISSN 0254-9077 ; 0002-9955 ; 0098-7484
    DOI 10.1001/jama.2023.4405
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.88: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Renin-Angiotensin System Inhibitors and the COVID-19 Pandemic.

    Muchaili, Lweendo / Mweene, Bislom C / Masenga, Sepiso K

    American journal of hypertension

    2023  Volume 36, Issue 7, Page(s) 360–362

    MeSH term(s) Humans ; COVID-19 ; Renin-Angiotensin System/drug effects ; Pandemics ; SARS-CoV-2 ; Peptidyl-Dipeptidase A/metabolism ; Antihypertensive Agents/pharmacology
    Chemical Substances Peptidyl-Dipeptidase A (EC 3.4.15.1) ; Antihypertensive Agents
    Language English
    Publishing date 2023-04-03
    Publishing country United States
    Document type Editorial ; Research Support, N.I.H., Extramural ; Comment
    ZDB-ID 639383-4
    ISSN 1941-7225 ; 1879-1905 ; 0895-7061
    ISSN (online) 1941-7225 ; 1879-1905
    ISSN 0895-7061
    DOI 10.1093/ajh/hpad031
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2329: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Inhibitoren des Renin-Angiotensin-Aldosteron-Systems bei COVID-19

    Kompakt Pneumologie

    2021  Volume -, Issue 7, Page(s) 42

    Language German
    Document type Article
    ZDB-ID 2301513-5
    ISSN 2199-0573
    Database Current Contents Medicine

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 7033/X: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Renin-angiotensin-aldosterone system inhibitors and the COVID-19 epidemic.

    Silva-Cardoso, José / Moreira, Emilia

    Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology

    2022  Volume 41, Issue 10, Page(s) 831–832

    MeSH term(s) Angiotensin Receptor Antagonists/therapeutic use ; Angiotensin-Converting Enzyme Inhibitors/therapeutic use ; COVID-19 ; Humans ; Renin-Angiotensin System
    Chemical Substances Angiotensin Receptor Antagonists ; Angiotensin-Converting Enzyme Inhibitors
    Language English
    Publishing date 2022-08-26
    Publishing country Portugal
    Document type Editorial ; Comment
    ZDB-ID 632718-7
    ISSN 2174-2030 ; 0870-2551 ; 0304-4750
    ISSN (online) 2174-2030
    ISSN 0870-2551 ; 0304-4750
    DOI 10.1016/j.repc.2022.08.006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 2865: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Impact of renin-angiotensin-aldosterone system inhibitors on COVID-19.

    Matsuzawa, Yasushi / Kimura, Kazuo / Ogawa, Hisao / Tamura, Kouichi

    Hypertension research : official journal of the Japanese Society of Hypertension

    2022  Volume 45, Issue 7, Page(s) 1147–1153

    Abstract: ... of renin-angiotensin system (RAS) inhibitors in COVID-19 have been debated as favorable, harmful, or neutral. Angiotensin ... profile of RAS inhibitors in COVID-19; however, this finding remains unclear. Further prospective studies ... are warranted to confirm the role of RAS inhibitors in COVID-19. In this review, we summarize ...

    Abstract Since the onset of the coronavirus disease 2019 (COVID-19) pandemic, the possible roles of renin-angiotensin system (RAS) inhibitors in COVID-19 have been debated as favorable, harmful, or neutral. Angiotensin-converting enzyme 2 (ACE2) not only is the entry route of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection but also triggers a major mechanism of COVID-19 aggravation by promoting tissue RAS dysregulation, which induces a hyperinflammatory state in several organs, leading to lung injury, hematological alterations, and immunological dysregulation. ACE inhibitors and angiotensin II type-1 receptor blockers (ARBs) inhibit the detrimental hyperactivation of the RAS by SARS-CoV-2 and increase the expression of ACE2, which is a counter-regulator of the RAS. Several studies have investigated the beneficial profile of RAS inhibitors in COVID-19; however, this finding remains unclear. Further prospective studies are warranted to confirm the role of RAS inhibitors in COVID-19. In this review, we summarize the potential effects of RAS inhibitors that have come to light thus far and review the impact of RAS inhibitors on COVID-19.
    MeSH term(s) Angiotensin Receptor Antagonists/pharmacology ; Angiotensin Receptor Antagonists/therapeutic use ; Angiotensin-Converting Enzyme 2 ; Angiotensin-Converting Enzyme Inhibitors/pharmacology ; Angiotensin-Converting Enzyme Inhibitors/therapeutic use ; COVID-19 ; Humans ; Peptidyl-Dipeptidase A/metabolism ; Renin-Angiotensin System ; SARS-CoV-2
    Chemical Substances Angiotensin Receptor Antagonists ; Angiotensin-Converting Enzyme Inhibitors ; Peptidyl-Dipeptidase A (EC 3.4.15.1) ; Angiotensin-Converting Enzyme 2 (EC 3.4.17.23)
    Language English
    Publishing date 2022-05-18
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1175297-x
    ISSN 1348-4214 ; 0916-9636
    ISSN (online) 1348-4214
    ISSN 0916-9636
    DOI 10.1038/s41440-022-00922-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3898: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Long-term effects of discontinuing renin-angiotensin system inhibitors in COVID-19.

    Theurl, Fabian / Sappler, Nikolay / Rizas, Konstantinos D / Massberg, Steffen / Bauer, Axel / Schreinlechner, Michael

    Respirology (Carlton, Vic.)

    2022  Volume 27, Issue 9, Page(s) 788–790

    MeSH term(s) Angiotensin Receptor Antagonists/pharmacology ; Angiotensin Receptor Antagonists/therapeutic use ; Antihypertensive Agents/pharmacology ; Antihypertensive Agents/therapeutic use ; COVID-19/drug therapy ; Humans ; Hypertension/drug therapy ; Renin-Angiotensin System ; SARS-CoV-2
    Chemical Substances Angiotensin Receptor Antagonists ; Antihypertensive Agents
    Language English
    Publishing date 2022-06-07
    Publishing country Australia
    Document type Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 1435849-9
    ISSN 1440-1843 ; 1323-7799
    ISSN (online) 1440-1843
    ISSN 1323-7799
    DOI 10.1111/resp.14306
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4957: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Potential use of renin-angiotensin-aldosterone system inhibitors to reduce COVID-19 severity.

    Gonçalves, Jorge / Santos, Catarina D / Fresco, Paula / Fernandez-Llimos, Fernando

    Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology

    2023  Volume 42, Issue 4, Page(s) 373–383

    Abstract: ... the potential therapeutic benefits of renin-angiotensin-aldosterone system inhibitors should be urgently ... angiotensin receptor blockers were associated with better prognosis for COVID-19. Therefore, pragmatic trials to assess ... SARS-CoV-2 infection and its clinical manifestations (COVID-19) quickly evolved to a pandemic and ...

    Abstract SARS-CoV-2 infection and its clinical manifestations (COVID-19) quickly evolved to a pandemic and a global public health emergency. The limited effectivity of available treatments aimed at reducing virus replication and the lessons learned from other coronavirus infections (SARS-CoV-1 or NL63) that share the internalization process of SARS-CoV-2, led us to revisit the COVID-19 pathogenesis and potential treatments. Virus protein S binds to the angiotensin-converting enzyme 2 (ACE2) initiating the internalization process. Endosome formation removes ACE2 from the cellular membrane preventing its counter-regulative effect mediated by the metabolism of angiotensin II to angiotensin (1-7). Internalized virus-ACE2 complexes have been identified for these coronaviruses. SARS-CoV-2 presents the highest affinity for ACE2 and produces the most severe symptoms. Assuming ACE2 internalization is the trigger for COVID-19 pathogenesis, accumulation of angiotensin II can be viewed as the potential cause of symptoms. Angiotensin II is a strong vasoconstrictor, but has also important roles in hypertrophy, inflammation, remodeling, and apoptosis. Higher levels of ACE2 in the lungs explain the acute respiratory distress syndrome as primary symptoms. Most of the described findings and clinical manifestations of COVID-19, including increased interleukin levels, endothelial inflammation, hypercoagulability, myocarditis, dysgeusia, inflammatory neuropathies, epileptic seizures and memory disorders can be explained by excessive angiotensin II levels. Several meta-analyses have demonstrated that previous use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers were associated with better prognosis for COVID-19. Therefore, pragmatic trials to assess the potential therapeutic benefits of renin-angiotensin-aldosterone system inhibitors should be urgently promoted by health authorities to widen the therapeutic options for COVID-19.
    MeSH term(s) Humans ; Renin-Angiotensin System ; COVID-19 ; Angiotensin-Converting Enzyme 2/metabolism ; Angiotensin-Converting Enzyme 2/pharmacology ; SARS-CoV-2/metabolism ; Angiotensin II/metabolism ; Angiotensin II/pharmacology ; Peptidyl-Dipeptidase A/metabolism ; Peptidyl-Dipeptidase A/pharmacology ; Inflammation
    Chemical Substances Angiotensin-Converting Enzyme 2 (EC 3.4.17.23) ; Angiotensin II (11128-99-7) ; Peptidyl-Dipeptidase A (EC 3.4.15.1)
    Language Portuguese
    Publishing date 2023-03-07
    Publishing country Portugal
    Document type Journal Article ; Review
    ZDB-ID 632718-7
    ISSN 2174-2030 ; 0870-2551 ; 0304-4750
    ISSN (online) 2174-2030
    ISSN 0870-2551 ; 0304-4750
    DOI 10.1016/j.repc.2022.02.014
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 2865: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Prescription of renin-angiotensin system inhibitors in Japan during the COVID-19 pandemic: interrupted time series study.

    Miura, Ryosuke / Okada, Kouji

    Hypertension research : official journal of the Japanese Society of Hypertension

    2023  Volume 46, Issue 12, Page(s) 2593–2602

    Abstract: ... blocker (ARBs) prescription trends during the coronavirus disease 2019 (COVID-19) pandemic in Japan. Data ... 0.189). There was no suggestion that the prescribing of ACEIs and ARBs was affected by the COVID-19 ... We surveyed changes in angiotensin-converting enzyme inhibitor (ACEIs) and angiotensin II receptor ...

    Abstract We surveyed changes in angiotensin-converting enzyme inhibitor (ACEIs) and angiotensin II receptor blocker (ARBs) prescription trends during the coronavirus disease 2019 (COVID-19) pandemic in Japan. Data of 1,605,708 outpatients with hypertension were extracted from the Medical Data Vision database. Trends for prescription of ACEIs and ARBs were assessed by analyzing the proportion of these prescriptions in each month, between April 2018 and November 2020. The proportion of ARBs prescriptions changed significantly in trend between the peri-pandemic and pre-pandemic periods (-0.05%/month, P = 0.012). In contrast, the proportion of ACEIs prescriptions did not change significantly in trend in the peri-pandemic period (0.01%/month, P = 0.189). There was no suggestion that the prescribing of ACEIs and ARBs was affected by the COVID-19 pandemic.
    MeSH term(s) Humans ; COVID-19 ; Angiotensin-Converting Enzyme Inhibitors/therapeutic use ; Pandemics ; Angiotensin Receptor Antagonists/therapeutic use ; Renin-Angiotensin System ; Japan/epidemiology ; Interrupted Time Series Analysis ; Antihypertensive Agents/therapeutic use ; Hypertension/drug therapy ; Hypertension/epidemiology ; Prescriptions
    Chemical Substances Angiotensin-Converting Enzyme Inhibitors ; Angiotensin Receptor Antagonists ; Antihypertensive Agents
    Language English
    Publishing date 2023-07-18
    Publishing country England
    Document type Journal Article
    ZDB-ID 1175297-x
    ISSN 1348-4214 ; 0916-9636
    ISSN (online) 1348-4214
    ISSN 0916-9636
    DOI 10.1038/s41440-023-01373-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3898: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Discontinuation of Renin-Angiotensin System Inhibitors During the Early Stage of the COVID-19 Pandemic.

    Muntner, Paul / Foti, Kathryn / Wang, Zhixin / Alanaeme, Chibuike J / Choi, Eunhee / Bress, Adam P / Shimbo, Daichi / Kronish, Ian

    American journal of hypertension

    2023  Volume 36, Issue 7, Page(s) 404–410

    Abstract: ... use of renin-angiotensin system (RAS) inhibitors despite theoretical concerns that these medications ... could increase COVID-19 severity. Determining if patients discontinued RAS inhibitors during the COVID-19 ... the early stage of the COVID-19 pandemic. ...

    Abstract Background: In March and April 2020, medical societies published statements recommending continued use of renin-angiotensin system (RAS) inhibitors despite theoretical concerns that these medications could increase COVID-19 severity. Determining if patients discontinued RAS inhibitors during the COVID-19 pandemic could inform responses to future public health emergencies.
    Methods: We analyzed claims data from US adults with health insurance in the Marketscan database. We identified patients who filled a RAS inhibitor and were persistent, defined by not having a ≥30-day gap without medication available, and high adherence, defined by having medication available on ≥80% of days, from March 2019 to February 2020. Among these patients, we estimated the proportion who discontinued their RAS inhibitor (i.e., had ≥30 consecutive days without a RAS inhibitor available to take) between March and August 2020. For comparison, we estimated the proportion of patients that discontinued a RAS inhibitor between March and August 2019 after being persistent with high adherence from March 2018 to February 2019.
    Results: Among 816,380 adults who were persistent and adherent to a RAS inhibitor from March 2019 to February 2020, 10.8% discontinued this medication between March and August 2020. Among 822,873 adults who were persistent and adherent to a RAS inhibitor from March 2018 to February 2019, 11.7% discontinued this medication between March and August 2019. The multivariable-adjusted relative risk for RAS inhibitor discontinuation in 2020 vs. 2019 was 0.94 (95% CI 0.93-0.95).
    Conclusions: There was no evidence of an increase in RAS inhibitor discontinuation during the early stage of the COVID-19 pandemic.
    MeSH term(s) Adult ; Humans ; COVID-19/epidemiology ; Angiotensin-Converting Enzyme Inhibitors/adverse effects ; Renin-Angiotensin System ; Pandemics ; Antihypertensive Agents/therapeutic use ; Enzyme Inhibitors/pharmacology ; Angiotensin Receptor Antagonists/adverse effects
    Chemical Substances Angiotensin-Converting Enzyme Inhibitors ; Antihypertensive Agents ; Enzyme Inhibitors ; Angiotensin Receptor Antagonists
    Language English
    Publishing date 2023-03-24
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 639383-4
    ISSN 1941-7225 ; 1879-1905 ; 0895-7061
    ISSN (online) 1941-7225 ; 1879-1905
    ISSN 0895-7061
    DOI 10.1093/ajh/hpad027
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2329: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Renin-Angiotensin-Aldosterone System Inhibitors in Covid-19.

    Lubel, John / Garg, Mayur

    The New England journal of medicine

    2020  Volume 382, Issue 24, Page(s) e92

    MeSH term(s) Betacoronavirus ; COVID-19 ; Coronavirus Infections ; Humans ; Pandemics ; Pneumonia, Viral ; Renin-Angiotensin System ; SARS-CoV-2
    Keywords covid19
    Language English
    Publishing date 2020-05-19
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMc2013707
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.34: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top